MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-04-2026
Country |
 USA |
IPO year |
1991 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
105 M |
Market Cap[1] |
$ 76.7 B |
EBITDA (LTM) |
$ 4.1 B |
P/E (LTM) |
15.87 |
P/S (LTM) |
5.52 |
EPS (LTM) |
46.47 |
Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development and production of innovative medical treatments. The company was founded in 1988 in New York.
Regeneron Pharmaceuticals' main areas of focus are research and development of drugs for the treatment of various diseases, including oncological, autoimmune, infectious, and others.
One of the company's most well-known products is Eylea, which is used to treat age-related macular degeneration. In addition, Regeneron Pharmaceuticals is developing drugs for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and other conditions.
The company invests heavily in scientific research and development to create innovative and effective drugs. Regeneron Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.
Regeneron Pharmaceuticals has a wide network of distributors and partners around the world, enabling it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
$ 28.46 | 3.45 % | $ 319 M | Nasdaq Global Select Market,SPB | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 221.88 | -0.87 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Axsome Therapeutics
AXSM
|
$ 156.92 | -1.23 % | $ 7.81 B | Nasdaq Global Market,SPB | USA |
 |
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Pharming Group N.V.
PHAR
|
$ 15.36 | -0.71 % | $ 7.59 B | Nasdaq Global Select Market |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.37 | -4.2 % | $ 350 M | Nasdaq Global Select Market |  Britain |
 |
Kamada Ltd.
KMDA
|
$ 8.5 | -1.39 % | $ 260 M | Nasdaq Global Select Market |  Israel |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Benitec Biopharma
BNTC
|
$ 10.98 | -4.52 % | $ 452 M | Nasdaq Capital Market | USA |
 |
Inventiva S.A.
IVA
|
$ 5.78 | -4.3 % | $ 138 M | Nasdaq Global Market | France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Compugen Ltd.
CGEN
|
$ 2.09 | -0.95 % | $ 195 M | Nasdaq Global Market,SPB | Israel |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 1.21 | -3.97 % | $ 71.5 M | Nasdaq Global Market | Britain |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
PainReform Ltd.
PRFX
|
$ 2.28 | -0.44 % | $ 1.03 M | Nasdaq Capital Market | Israel |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
|
Foghorn Therapeutics
FHTX
|
$ 5.0 | 2.25 % | $ 315 M | Nasdaq Global Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.4 | -3.68 % | $ 1.02 B | Nasdaq Global Select Market | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
$ 54.13 | -1.64 % | $ 10.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Curis
CRIS
|
$ 0.77 | 1.89 % | $ 4.86 M | Nasdaq Global Market | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.52 | -5.59 % | $ 178 M | Nasdaq Global Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Burford Capital Limited
BUR
|
$ 7.7 | -5.87 % | $ 1.29 B | NYSE | Britain |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectis S.A.
CLLS
|
$ 3.34 | -4.02 % | $ 116 M | Nasdaq Global Market | France |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.24 | -2.97 % | $ 704 M | Nasdaq Global Select Market | Canada |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.8 | -1.1 % | $ 120 M | Nasdaq Capital Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Cabaletta Bio
CABA
|
$ 2.94 | -3.29 % | $ 3.43 M | Nasdaq Global Select Market | USA |
 |
Iterum Therapeutics
ITRM
|
$ 0.16 | -5.45 % | $ 3.15 M | Nasdaq Global Select Market |  Irlanda |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.